Skip to main content

Digital Pathology Market Size [2022-2028] | Industry Size, Share, Growth & Forecast Analysis Report

Written by Customer Service on . Posted in Mergers And Acquisitions.

Key Prominent Players Covered in the Digital Pathology Market Research Report are 3DHISTECH – The Digital Pathology Company, Mikroscan Technologies, Inc., Objective Pathology Services, Hamamatsu Photonics, Roche Diagnostics Danmark, Primera Technology, Biogenuix Medsystems Pvt Ltd and other key market players

Pune, India, Feb. 22, 2022 (GLOBE NEWSWIRE) — The global digital pathology market size is expected to grow due to the rising technological advancements in the healthcare sector during the forecast period. Fortune Business Insights™ publishes this information in an upcoming report titled, “Digital Pathology Market, 2021-2028”.

At Fortune Business Insights, we offer meticulous studies to help healthcare organizations get into the mind of their customer and design winning growth strategies. Our services therefore span across a gamut of markets within the healthcare sector. These include the healthcare IT, medical devices, pharmaceutical, biotechnology, diagnostics and other healthcare services. Our reports contain information, keeping in focus the specific requirements of key stakeholders.


Sample PDF Brochure:  https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/digital-pathology-market-100229

For instance, within the healthcare industry our product-offering includes:
1. Market Snapshot Reports – Quick market assessments to help our clients derive valuable insights on market size, prevailing competition, and others.
2. Disease Burden Reports – Reports estimating the burden of prevalent and rare disease conditions from a prevalence and cost of care perspective.
3. Market Landscape Reports – Get an executive-level blueprint of the market and valued recommendations to determine winning growth strategies.


Digital Pathology Market Development:

  • January 2019: Roche introduced its new software for digital pathologies, uPath. This software provides properties to examine high-resolution images and patient conditions in a single view.


Market Growth Reasons:

  • Regional Expansion and Development of Innovative Products to offer Growth Opportunity for Key Players
  • Rise in Awareness and Favorable Guidelines to Boost Product Demand
  • Strategic Initiatives to Boost the Market Growth
  • Positive Reimbursement Scenario to Boost Market Growth
  • Increased Applications to Propel Market Growth


For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/digital-pathology-market-100229

The Digital Pathology Market development is relied upon to develop during the conjecture time frame because of the expanding usage of arising innovations in the medical services industry. The public authority drives forced in fragmented districts are expected to foster the market reach.

In April 2017, the FDA gave its endorsement to Philips’ Intellisite Pathology (PIPS) for assembling and deal in the U.S. This was the very first computerized pathology framework in the market with FDA leeway.

Vital participants in the market centre on framing vital collusions with supporting associations in the medical services and drug area. Putting resources into R&D and creating progressed frameworks will permit organizations to work on their presentation by expanding efficiency, bringing about benefit. Development and item separation methodologies further develop item portfolio and gain upper hand in the business.


Quick Buy Digital Pathology Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100229


Market Segmentations:

By technology, the Digital Pathology Market is partitioned into entire slide imaging, picture investigation data, advanced cytopathology, computerized holography, microscopy, and others. Based on application, the market is isolated into hematology investigation, platelet counting, pee silt examination, infection analysis, and others. The market is fragmented into pathology labs, medical clinics, drug and biotechnology organizations, indicative focuses, and others in view of the end-clients.


Key Players Covered in the Digital Pathology Market Report:

  • 3DHistech Inc. (U.K.)
  • ZIH Corp (U.S.)
  • Mikroscan Technologies Inc. (U.S.)
  • Objective Pathology Services (Canada)
  • Hamamatsu Photonics K.K. (Japan)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Primera Technology (U.S.)
  • CEREBRUM CORP (U.S.)
  • Nikon Corporation (Japan)
  • Biogenuix (India)
  • Indica Labs Inc. (U.S.)
  • Koninklijke Philips N.V. (Netherlands)
  • Sectra AB (Sweden)
  • Inspirata (U.S.)
  • LigoLAb (U.S.)
  • Leica Biosystems Nussloch GmbH (Germany)


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/queries/digital-pathology-market-100229


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.